​

Sarepta Therapeutics (SRPT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SRPT Stock Forecast

Sarepta Therapeutics (SRPT) stock forecast, based on 54 Wall Street analysts, predicts a 12-month average price target of $25.92, with a high of $75.00 and a low of $10.00. This represents a 19.17% increase from the last price of $21.75.

- $40 $80 $120 $160 $200 High: $75 Avg: $25.92 Low: $10 Last Closed Price: $21.75

SRPT Stock Rating

Sarepta Therapeutics stock's rating consensus is Buy, based on 54 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 30 Buy (55.56%), 19 Hold (35.19%), 5 Sell (9.26%), and 0 Strong Sell (0.00%).

Buy
Total 54 0 5 19 30 Strong Sell Sell Hold Buy Strong Buy

SRPT Price Target Upside V Benchmarks

TypeNameUpside
StockSarepta Therapeutics19.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2617
Avg Price Target$26.00$21.50$31.82
Last Closing Price$21.75$21.75$21.75
Upside/Downside19.54%-1.15%46.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-6143225
Nov, 2515153226
Oct, 2515163227
Sep, 2515173228
Aug, 2514183228
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 09, 2025Wedbush$32.00$21.8646.39%47.13%
Nov 25, 2025Bernstein$20.00$18.915.76%-8.05%
Nov 05, 2025Barclays$20.00$16.2023.46%-8.05%
Nov 05, 2025Uy EarMizuho Securities$26.00$16.2060.49%19.54%
Nov 04, 2025Brian SkorneyRobert W. Baird$15.00$24.45-38.65%-31.03%
Oct 30, 2025Biren AminPiper Sandler$16.00$23.45-31.77%-26.44%
Sep 09, 2025Joseph SchwartzLeerink Partners$15.00$17.57-14.63%-31.03%
Aug 21, 2025Barclays$22.00$20.069.67%1.15%
Aug 15, 2025David HoangDeutsche Bank$12.00$20.30-40.89%-44.83%
Jul 22, 2025Gena WangBarclays$18.00$13.3235.14%-17.24%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 09, 2025WedbushBuyOutperforminitialise
Nov 25, 2025BernsteinMarket PerformMarket Performhold
Oct 30, 2025Piper SandlerNeutralNeutralhold
Sep 22, 2025BMO CapitalMarket PerformOutperformupgrade
Aug 25, 2025H.C. WainwrightSellSellhold
Aug 15, 2025Deutsche BankSellSellhold
Aug 04, 2025RBC CapitalSector PerformSector Performhold
Jul 27, 2025BarclaysOverweightUnderweightdowngrade
Jul 22, 2025CitigroupSellSellhold
Jul 21, 2025BMO CapitalMarket PerformMarket Performhold

Financial Forecast

EPS Forecast

$-10 $-3 $4 $11 $18 $25 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-7.11$-5.15$-8.03$-5.80$2.47----
Avg Forecast$-6.55$-5.11$-8.06$-6.57$2.41$11.64$15.52$14.87$15.91
High Forecast$-6.11$-4.77$-6.17$-6.18$2.94$16.50$21.20$18.54$17.88
Low Forecast$-7.25$-5.66$-8.95$-7.57$1.72$3.67$10.82$10.96$12.75
Surprise %8.55%0.78%-0.37%-11.72%2.49%----

Revenue Forecast

$500M $1B $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$540.10M$701.89M$933.01M$1.24B$1.90B----
Avg Forecast$540.17M$695.42M$924.70M$1.23B$1.83B$3.12B$3.94B$4.20B$4.43B
High Forecast$584.61M$752.63M$1.00B$1.24B$1.86B$3.42B$3.95B$4.22B$4.85B
Low Forecast$512.45M$659.73M$758.15M$1.21B$1.77B$2.39B$3.93B$4.19B$3.75B
Surprise %-0.01%0.93%0.90%0.86%4.10%----

Net Income Forecast

$-1B $-400M $200M $800M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-554.13M$-418.78M$-703.49M$-535.98M$235.24M----
Avg Forecast$-604.74M$-435.96M$-421.18M$-535.98M$215.18M$1.10B$1.54B$1.66B$1.47B
High Forecast$-564.40M$-348.77M$-336.95M$-428.78M$271.43M$1.52B$1.96B$1.71B$1.65B
Low Forecast$-669.42M$-523.15M$-505.42M$-643.17M$158.93M$338.71M$999.68M$1.01B$1.18B
Surprise %-8.37%-3.94%67.03%-9.32%----

SRPT Forecast FAQ

Is Sarepta Therapeutics stock a buy?

Sarepta Therapeutics stock has a consensus rating of Buy, based on 54 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 30 Buy, 19 Hold, 5 Sell, and 0 Strong Sell, reflecting a consensus that Sarepta Therapeutics is a favorable investment for most analysts.

What is Sarepta Therapeutics's price target?

Sarepta Therapeutics's price target, set by 54 Wall Street analysts, averages $25.92 over the next 12 months. The price target range spans from $10 at the low end to $75 at the high end, suggesting a potential 19.17% change from the previous closing price of $21.75.

How does Sarepta Therapeutics stock forecast compare to its benchmarks?

Sarepta Therapeutics's stock forecast shows a 19.17% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Sarepta Therapeutics over the past three months?

  • December 2025: 0% Strong Buy, 24.00% Buy, 56.00% Hold, 12.00% Sell, 8.00% Strong Sell.
  • November 2025: 3.85% Strong Buy, 19.23% Buy, 57.69% Hold, 11.54% Sell, 7.69% Strong Sell.
  • October 2025: 3.70% Strong Buy, 18.52% Buy, 59.26% Hold, 11.11% Sell, 7.41% Strong Sell.

What is Sarepta Therapeutics’s EPS forecast?

Sarepta Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $11.64, marking a 371.26% increase from the reported $2.47 in 2024. Estimates for the following years are $15.52 in 2026, $14.87 in 2027, and $15.91 in 2028.

What is Sarepta Therapeutics’s revenue forecast?

Sarepta Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.12B, reflecting a 64.07% increase from the reported $1.9B in 2024. The forecast for 2026 is $3.94B, followed by $4.2B for 2027, and $4.43B for 2028.

What is Sarepta Therapeutics’s net income forecast?

Sarepta Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $1.1B, representing an 367.14% increase from the reported $235.24M in 2024. Projections indicate $1.54B in 2026, $1.66B in 2027, and $1.47B in 2028.